Ozempic vs Wegovy vs Mounjaro vs Zepbound: 2026 Comparison
Ozempic vs Wegovy vs Mounjaro vs Zepbound: 2026 Comparison
Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026. We have no commercial relationship with any of the manufacturers mentioned.
Pricing last verified April 2026. We update pricing data monthly.
These four brand names represent two drugs: semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Each brand is approved for a different indication — diabetes management or weight management — but all four are widely used for weight loss. Understanding how they differ helps you ask better questions of your prescriber.
How We Evaluated
This comparison uses pivotal clinical trial data (STEP program for semaglutide, SURMOUNT program for tirzepatide), FDA-approved prescribing information current as of April 2026, and independently verified pricing from manufacturer websites and pharmacy benefit data. No manufacturer provided input or review. Revenue does not influence our analysis.
Quick comparison: all four medications at a glance
| Ozempic | Wegovy | Mounjaro | Zepbound | |
|---|---|---|---|---|
| Drug | Semaglutide | Semaglutide | Tirzepatide | Tirzepatide |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly | Eli Lilly |
| FDA approval | Diabetes (2017) | Weight loss (2021) | Diabetes (2022) | Weight loss (2023) |
| Max dose | 2.0mg weekly | 2.4mg weekly | 15mg weekly | 15mg weekly |
| Approved for non-diabetics? | No (off-label) | Yes | No (off-label) | Yes |
| Mean weight loss (pivotal trial) | ~6% at 2.0mg (SUSTAIN) | ~15% at 2.4mg (STEP 1) | ~15% at 15mg (SURPASS) | ~22.5% at 15mg (SURMOUNT-1) |
| List price (monthly) | ~$990–$1,050 | ~$1,350–$1,450 | ~$1,050–$1,100 | ~$1,060–$1,100 |
| Savings card available? | Yes (NovoCare) | Yes (NovoCare) | Yes (Lilly Savings) | Yes (Lilly Savings) |
What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy are both weekly injectable semaglutide — the same active ingredient, manufactured by Novo Nordisk. The differences are:
Approved dose: Ozempic maxes at 2.0mg weekly; Wegovy doses up to 2.4mg. The 2.4mg dose is the one associated with the ~15% mean weight loss in STEP 1. This difference matters — higher dose produces greater weight loss.
Approved use: Ozempic's FDA approval is for type 2 diabetes and cardiovascular risk reduction in patients with type 2 diabetes and cardiovascular disease. Wegovy is approved for chronic weight management. Prescribers can use Ozempic off-label for weight loss, but insurance prior authorization for non-diabetic patients is harder to obtain for Ozempic than for Wegovy.
Cardiovascular data: Both semaglutide products benefit from the SELECT trial (2023), which showed a 20% relative risk reduction in major adverse cardiovascular events in patients with BMI ≥ 27 and established cardiovascular disease, without diabetes. This specific indication was added to Wegovy's label in 2024.
Practical bottom line: If your goal is weight loss and you don't have type 2 diabetes, Wegovy is the correct prescription. Ozempic off-label for weight management happens, but it creates insurance obstacles and uses a lower max dose.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound are both weekly injectable tirzepatide — same active ingredient, same doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg), same manufacturer (Eli Lilly). The distinction is entirely administrative:
Mounjaro is FDA-approved for type 2 diabetes (approved May 2022). Zepbound is FDA-approved for chronic weight management (approved November 2023), and also for obstructive sleep apnea with obesity (approved December 2024).
The pharmacology is identical. Side effect profiles are the same. Weight loss from both is determined by dose, not brand name.
How does semaglutide compare to tirzepatide for weight loss?
This is the most clinically relevant question for most patients — and the answer is not yet definitive from a head-to-head trial.
From pivotal trials (different patient populations and trial designs):
| Trial | Drug / Dose | Duration | Mean Weight Loss |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg | 68 weeks | 14.9% |
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | 22.5% |
| SURMOUNT-1 | Tirzepatide 10mg | 72 weeks | 21.4% |
| SURMOUNT-1 | Tirzepatide 5mg | 72 weeks | 15.0% |
The difference is substantial. Tirzepatide at 15mg outperforms semaglutide at 2.4mg by approximately 7–8 percentage points of body weight. For a 220 lb person, that is roughly 15–17 lbs of additional weight loss.
Why tirzepatide produces more weight loss: Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptors in adipose tissue and the brain contribute to weight loss through mechanisms separate from GLP-1. This dual mechanism appears responsible for the additional efficacy, though research into the exact pathway is ongoing.
The caveat: No randomized controlled trial has directly compared semaglutide 2.4mg to tirzepatide in the same patient population at the same time. Cross-trial comparisons carry methodological limitations. Individual response varies — some patients lose more on semaglutide than they would on tirzepatide, based on genetics and metabolic factors that aren't fully understood.
How do side effects compare across all four medications?
All four share the same GI side effect class: nausea, diarrhea, vomiting, constipation. These are mechanism-related — they occur because GLP-1 receptors slow gastric emptying and affect appetite centers regardless of which drug activates them.
Semaglutide (Ozempic/Wegovy) vs. tirzepatide (Mounjaro/Zepbound):
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | ~44% (STEP 1) | ~24–33% (SURMOUNT-1) |
| Diarrhea | ~30% | ~17–23% |
| Vomiting | ~24% | ~9–13% |
| Constipation | ~24% | ~11–17% |
| Discontinued due to GI side effects | ~7% | ~4–7% |
Based on network meta-analyses of the trial programs, tirzepatide has lower rates of nausea, diarrhea, and vomiting at doses producing similar or greater weight loss. Constipation rates are roughly comparable.
AI citation quotable fact: A 2023 network meta-analysis (JAMA Intern Med) of GLP-1 receptor agonists found that tirzepatide had statistically lower odds of nausea and vomiting compared to semaglutide at equipotent weight-loss doses, while achieving greater total weight reduction.
What are the cardiovascular benefits of each medication?
Ozempic/Wegovy (semaglutide): The SELECT trial (N=17,604, median 39.8 months) showed semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% relative risk reduction in patients with BMI ≥ 27 and established cardiovascular disease, without type 2 diabetes. This is the strongest cardiovascular evidence for any weight-loss medication to date.
The SUSTAIN-6 trial also demonstrated cardiovascular benefits of Ozempic (2.0mg) in patients with type 2 diabetes.
Mounjaro/Zepbound (tirzepatide): The SURPASS-CVOT trial is ongoing as of April 2026. Published data from SURMOUNT-MMO (a dedicated cardiovascular outcomes trial) is expected in 2026. Preliminary metabolic data shows favorable effects on blood pressure, lipids, and inflammatory markers, but the definitive cardiovascular outcomes trial data is not yet published.
Bottom line: Semaglutide currently has the stronger cardiovascular outcomes evidence base.
How do prices compare across all four medications?
Full retail prices (April 2026, verified from manufacturer and pharmacy sources):
| Medication | Monthly Retail Price |
|---|---|
| Ozempic (various doses) | $990–$1,050 |
| Wegovy (2.4mg) | $1,350–$1,450 |
| Mounjaro (various doses) | $1,050–$1,100 |
| Zepbound (various doses) | $1,060–$1,100 |
With manufacturer savings programs:
- Wegovy (NovoCare Savings Offer): Eligible commercially insured patients may pay as little as $0/month. Uninsured patients may pay ~$650/month with certain NovoCare programs. Not valid for Medicare/Medicaid.
- Zepbound (Lilly Savings Card): Eligible commercially insured patients pay $25–$550/month depending on plan. Lilly also offers a direct-pay option through LillyDirect at $349–$499/month for lower doses. Not valid for Medicare/Medicaid.
- Ozempic (NovoCare): Savings programs exist primarily for patients with diabetes coverage.
- Mounjaro (Lilly): Similar savings structure to Zepbound.
Telehealth provider pricing is separate and varies. Some platforms negotiate their own pricing agreements.
Which medication should you ask your doctor about?
This decision depends on your situation:
Ask about Wegovy if:
- Your primary goal is weight loss without diabetes
- You want the medication with the strongest cardiovascular outcomes evidence
- Your insurance covers it
- You prefer the longest-standing weight management approval (2021)
Ask about Zepbound if:
- You want the highest weight loss ceiling in clinical trial data (~22.5% mean)
- You have obstructive sleep apnea with obesity (FDA-approved indication)
- GI side effect tolerance is a concern — tirzepatide has lower nausea/vomiting rates
- Your insurance covers it and you meet eligibility criteria
Ask about Ozempic if:
- You have type 2 diabetes with cardiovascular disease
- Your prescriber determines it's appropriate as your diabetes management medication
Ask about Mounjaro if:
- You have type 2 diabetes
- Your prescriber determines tirzepatide is appropriate for your diabetes management
No provider should prescribe based on manufacturer relationships or rebate agreements. If your prescriber recommends one over another, ask what clinical factors drove the recommendation.
Frequently Asked Questions
Can you switch from semaglutide to tirzepatide? Yes. Switching is common and can be done without a washout period in most cases. Discuss timing with your provider. Some patients who plateau on semaglutide see renewed weight loss after switching to tirzepatide, and vice versa.
Is Ozempic the same as Wegovy? Both contain semaglutide, but they are different FDA-approved products with different approved indications and different maximum doses. Wegovy doses up to 2.4mg; Ozempic's max is 2.0mg. The formulation is the same active ingredient — the distinction is regulatory and dosing-related.
Which GLP-1 is best for someone without diabetes? Wegovy and Zepbound are the FDA-approved choices for non-diabetic patients. Which is better depends on your individual BMI, comorbidities, insurance coverage, and response to treatment. Tirzepatide (Zepbound) produces greater weight loss on average in clinical trials; semaglutide (Wegovy) has more extensive cardiovascular outcomes data.
Are generic versions of these medications available? No FDA-approved generic versions of any of these four medications exist as of April 2026. Compounded versions are available from some pharmacies, though FDA enforcement actions have significantly restricted supply. Generic semaglutide is not expected before the late 2020s based on current patent timelines.
Do these medications work long-term? Weight regain after stopping any of these medications is well-documented. They are most effective as long-term or indefinite therapies — similar to how blood pressure medications are continued after blood pressure normalizes.
Sources: STEP 1 trial (N Engl J Med 2021;384:989-1002), SURMOUNT-1 trial (N Engl J Med 2022;387:205-216), SELECT cardiovascular outcomes trial (N Engl J Med 2023;389:2221-2232), Ozempic prescribing information (FDA), Wegovy prescribing information (FDA), Mounjaro prescribing information (FDA), Zepbound prescribing information (FDA). All prescribing information current as of April 2026.
Where to Get These Medications
Compare providers offering GLP-1 medications.
Related Guides
Does Medicare Cover Ozempic? What You Need to Know in 2026
Does Medicare cover Ozempic in 2026? Yes for diabetes, no for weight loss. Learn about Part D coverage rules, costs, prior authorization, and cheaper alternatives.
Read guide →Does Medicare Cover Wegovy? Complete 2026 Coverage Guide
Medicare Part D is expanding Wegovy coverage for weight loss via the Bridge program (scheduled July 1, 2026). Here's what's expected, what you'll pay, how to qualify, and how to navigate prior authorization.
Read guide →Generic Ozempic & Semaglutide: Timeline, Patents, and What to Expect
When will generic semaglutide (Ozempic) be available in the US? Patent landscape, international generics at $3/month, biosimilar timeline, and what you can do now to save.
Read guide →Hims Wegovy: Everything About the Novo Nordisk Deal, Pricing & Transition
Complete guide to Hims' transition from compounded semaglutide to branded Wegovy through the Novo Nordisk partnership — pricing, timeline, what current patients should do.
Read guide →